Gangliosides in Neurodegeneration

Gangliosides in Neurodegeneration

Introduction

Gangliosides In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Gangliosides are sialic acid-containing glycosphingolipids highly enriched in neuronal membranes, particularly at synapses. They play crucial roles in neural development, synaptic transmission, and cellular signaling. Alterations in ganglioside metabolism are implicated in various neurodegenerative diseases. [@bgalnt]

Overview of Gangliosides

Structure and Classification

Gangliosides are composed of: [@sialylation]

• Ceramide backbone — sphingosine + fatty acid
• Oligosaccharide chain — glucose, galactose, N-acetylgalactosamine
• One or more sialic acid residues — determines ganglioside series

Major Brain Gangliosides

| Ganglioside | Abbreviation | Abundance | Location | [@links]
|-------------|--------------|-----------|----------| [@gangliosides]
| GM1 | GM1a | High | Synaptic membranes |
| GD1a | GD1a | High | Neuronal cell bodies |
| GD1b | GD1b | Moderate | Myelin, neurons |
| GT1b | GT1b | High | Presynaptic terminals |
| GQ1b | GQ1b | Moderate | Synaptic vesicles |

Regional Distribution

• GM1 — predominantly in gray matter, synaptic membranes
• GD1a — highest in cerebral cortex
• GT1b — enriched in presynaptic terminals
• Complex gangliosides — decrease with age

Gangliosides in Alzheimer's Disease

...

Gangliosides in Neurodegeneration

Introduction

Gangliosides In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Gangliosides are sialic acid-containing glycosphingolipids highly enriched in neuronal membranes, particularly at synapses. They play crucial roles in neural development, synaptic transmission, and cellular signaling. Alterations in ganglioside metabolism are implicated in various neurodegenerative diseases. [@bgalnt]

Overview of Gangliosides

Structure and Classification

Gangliosides are composed of: [@sialylation]

• Ceramide backbone — sphingosine + fatty acid
• Oligosaccharide chain — glucose, galactose, N-acetylgalactosamine
• One or more sialic acid residues — determines ganglioside series

Major Brain Gangliosides

| Ganglioside | Abbreviation | Abundance | Location | [@links]
|-------------|--------------|-----------|----------| [@gangliosides]
| GM1 | GM1a | High | Synaptic membranes |
| GD1a | GD1a | High | Neuronal cell bodies |
| GD1b | GD1b | Moderate | Myelin, neurons |
| GT1b | GT1b | High | Presynaptic terminals |
| GQ1b | GQ1b | Moderate | Synaptic vesicles |

Regional Distribution

• GM1 — predominantly in gray matter, synaptic membranes
• GD1a — highest in cerebral cortex
• GT1b — enriched in presynaptic terminals
• Complex gangliosides — decrease with age

Gangliosides in Alzheimer's Disease

Tau Internalization and Propagation

The 2024 study on ganglioside sialylation and tau internalization (PMID:41398374) revealed critical insights into how ganglioside modifications affect tau pathology:

Tau Internalization Mechanism — Neuronal uptake of proteopathic tau aggregates is integral to pathological spread throughout the brain. Gangliosides on neuronal membranes serve as receptors for tau entry.

Sialylation Effects — The sialylation state of gangliosides directly modulates tau internalization efficiency. Specific sialylated gangliosides (such as GD1a and GT1b) facilitate tau uptake while non-sialylated forms show reduced internalization.

Pathology Spread — Ganglioside-mediated tau internalization contributes to the stereotypical progression of tau pathology in Alzheimer's disease, spreading from entorhinal cortex to hippocampus and neocortex.

Therapeutic Implications — Modulating ganglioside sialylation represents a novel therapeutic strategy to:

• Reduce tau uptake by neurons
• Slow pathological spread
• Enhance clearance of internalized tau

Amyloid Interaction

Gangliosides interact with beta-amyloid in ways that affect both protein aggregation and clearance:

GM1 as seed — GM1 clusters may initiate Aβ aggregation

Membrane rafts — ganglioside-rich domains concentrate APP processing

Aβ binding — specific gangliosides (GM1, GD1a) bind Aβ

Aggregation modulation — gangliosides can accelerate or inhibit fibril formation

Synaptic Dysfunction

• GT1b and GQ1b are reduced in AD hippocampus
• GM1 loss disrupts synaptic signaling
• Ganglioside changes affect neurotransmitter release

Therapeutic Implications

• GM1 supplementation shows promise in animal models
• Ganglioside-based vaccines under investigation
• Targeting ganglioside-Aβ interactions

Gangliosides in Parkinson's Disease

Alpha-Synuclein Interaction

Gangliosides interact with alpha-synuclein through multiple mechanisms:

Membrane binding — α-Synuclein binds to lipid membranes containing gangliosides, particularly GM1 and GD1a. The amphipathic N-terminal region of α-syn has high affinity for negatively charged phospholipids and glycosphingolipids. Studies show GM1a clusters significantly increase α-synuclein membrane association, potentially seeding aggregation. [@soniou2019]

Aggregation modulation — GM1 inhibits α-syn fibrillization in a dose-dependent manner. In vitro studies demonstrate that GM1a can redirect α-syn into off-pathway oligomers rather than fibrils. This has led to therapeutic strategies targeting ganglioside-α-syn interactions. [@martinez2020]

Membrane permeability — Ganglioside clusters may form entry points for extracellular α-syn aggregates. The complex gangliosides (GT1b, GQ1b) create microdomains that facilitate protein transduction across the neuronal membrane. [@nakamura2017]

Cell-to-cell transmission — Ganglioside-rich lipid rafts participate in exosome formation and release, potentially facilitating α-syn propagation between neurons. [@emmanouilidou2010]

Membrane Composition Changes in PD

• Altered ganglioside composition in PD substantia nigra — Post-mortem studies reveal significant reduction in GM1 and GD1a in the substantia nigra of PD patients. This deficit precedes dopaminergic neuron loss in some cases, suggesting potential involvement in disease initiation. [@schneider2012]
• Reduced GM1 as biomarker — Peripheral blood GM1 levels show correlation with disease severity. Patients with more severe motor symptoms tend to have lower GM1 content in erythrocyte membranes. This has spurred interest in developing GM1 as a peripheral biomarker. [@cook2016]
• Therapeutic implications — GM1 supplementation has been tested in PD clinical trials. Early-phase studies showed modest benefit in motor scores, though larger trials are needed. Current approaches include GM1 analogs with improved BBB penetration. [@gorbunova2021]

Molecular Mechanisms of Ganglioside-Mediated Neurodegeneration

Membrane Raft Dysregulation

Gangliosides concentrate in lipid rafts—cholesterol-rich microdomains essential for neuronal signaling. In neurodegeneration:

Receptor clustering — Ganglioside rafts organize neurotransmitter receptors (glutamate, dopamine) and their signaling machinery. Altered ganglioside composition disrupts receptor trafficking and function.

APP processing — Lipid rafts concentrate β- and γ-secretase, influencing amyloid precursor protein processing. Ganglioside alterations shift APP toward amyloidogenic cleavage.

TROVE domain proteins — Ganglioside rafts host signaling proteins including receptor tyrosine kinases. Changes in raft composition affect neurotrophin signaling and neuronal survival.

Calcium homeostasis — Ganglioside-rich domains participate in calcium regulation. Disruption leads to excitotoxicity and impaired synaptic plasticity.

Ceramide Accumulation

Ganglioside catabolism produces ceramide, a pro-apoptotic lipid mediator:

Ceramide-induced apoptosis — Elevated ceramide activates caspase-dependent apoptosis pathways. In PD, increased ceramide levels in substantia nigra correlate with dopaminergic neuron loss.

Mitochondrial dysfunction — Ceramide directly impairs mitochondrial Complex I activity and promotes ROS generation. This creates a feed-forward cycle of oxidative stress.

Autophagy regulation — Ceramide stimulates autophagy, but excessive amounts lead to autophagic cell death. The balance is critical for neuronal survival.

Inflammation — Ceramide activates glial cells through TLR4 and other pattern recognition receptors, promoting neuroinflammation.

Sialidase Activity

Sialidases (neuraminidases) remove sialic acid from gangliosides, regulating their function:

NEU1 in neurodegeneration — Elevated NEU1 activity in AD brain leads to desialylated gangliosides, disrupting receptor function and promoting pathology.

NEU3 regulation — NEU3 preferentially acts on complex gangliosides. Its dysregulation affects cell surface receptor signaling.

Therapeutic targeting — Sialidase inhibitors represent a potential therapeutic approach to restore ganglioside patterns in neurodegeneration.

Therapeutic Implications in PD

• GM1 supplementation trials in PD patients
• Targeting ganglioside-α-syn interactions
• Modulating ganglioside biosynthesis

Gangliosides in Other Neurodegenerative Diseases

Huntington's Disease

• Altered ganglioside metabolism in HD — Multiple studies document reduced GM1 and complex gangliosides in the striatum and cortex of HD patients and mouse models. The huntingtin protein itself may interact with ganglioside biosynthetic enzymes. [@desplats2007]
• GM1 deficiency in striatum — The most affected region in HD shows the most severe ganglioside deficit. GM1 supplementation experiments in R6/1 mice show improved motor function and reduced striatal atrophy. [@diroma2021]
• Potential therapeutic target — Given the role of gangliosides in dopamine receptor signaling, restoring ganglioside homeostasis may help correct the dopaminergic dysfunction characteristic of HD.

Amyotrophic Lateral Sclerosis

• Changes in motor neuron gangliosides — ALS motor neurons show altered ganglioside profiles, including reduced GM1 and GD1a. Mutations in ganglioside-related genes have been identified in some familial ALS cases. [@lefler2021]
• GM1 deficiency in ALS models — SOD1 transgenic mice demonstrate progressive ganglioside loss in spinal cord motor neurons, correlating with disease progression.
• Ganglioside therapy trials — Early clinical trials testing GM1 supplementation in ALS showed mixed results, with some patients showing slowed progression but the evidence remaining inconclusive.

Multiple System Atrophy

• MSA shows specific ganglioside changes — Unlike PD, MSA (the olivopontocerebellar atrophy variant) shows preserved or increased certain gangliosides in affected regions, potentially offering a diagnostic distinction.
• Oligodendrocyte involvement — MSA features glial cytoplasmic inclusions containing α-synuclein. Ganglioside changes in oligodendrocytes may contribute to the myelin dysfunction seen in MSA.

Progressive Supranuclear Palsy

• PSP alterations — The subcortical degeneration in PSP is associated with specific ganglioside changes, particularly in the brainstem and basal ganglia. These differ from PD patterns. [@bernheimer2013]

Ganglioside Biosynthesis and Catabolism

Biosynthetic Pathway

The ganglioside biosynthesis pathway involves a series of glycosyltransferase reactions:

Catabolism

• Lysosomal storage diseases — defects cause gangliosidoses (Tay-Sachs, Sandhoff, GM1)
• Neuraminidase (NEU1-4) — removes sialic acid residues
• Glycosidases (GBA, GAA) — degrade oligosaccharide chain
• Ceramide degradation — acid ceramidase converts ceramide to sphingosine

Therapeutic Strategies

Current Approaches

| Approach | Target | Agent | Status | Evidence |
|----------|--------|-------|--------|----------|
| GM1 supplementation | Restore membrane GM1 | GM1 ganglioside | Phase 2 | Modest benefit in motor scores |
| Ganglioside synthesis modulators | ST3GAL5, B4GALT | Small molecules | Preclinical | Proof-of-concept in models |
| Sialidase inhibitors | NEU1-4 | Zanamivir analogs | Preclinical | In vitro activity |
| Gene therapy | Ganglioside metabolism genes | AAV-ST3GAL5 | Preclinical | Rescue in KO mice |
| Anti-ganglioside antibodies | Pathological gangliosides | Monoclonal antibodies | Research | Not yet in clinic |

GM1 Supplementation Trials

The most advanced clinical approach involves GM1 (monosialoganglioside) supplementation:

Historical trials (1990s) — Early open-label studies showed 30-40% improvement in UPDRS scores

Sham-controlled trial (2012) — Schneider et al. demonstrated safety but missed primary endpoint

Current Phase 2 (2024) — Optimized dosing (40mg IV daily for 5 days/month) showing better tolerability

Combination approaches — GM1 + exercise therapy showing synergistic effects in pilot studies

Challenges in Ganglioside-Targeted Therapy

BBB penetration — Large hydrophilic molecule limits CNS delivery

Immunogenicity — Anti-GM1 antibodies can cause peripheral neuropathy

Dosing optimization — Chronic vs. pulsed dosing protocols under investigation

Biomarker development — Need for patient selection biomarkers

Gangliosides in Lipid Rafts and Membrane Signaling

Lipid Raft Structure and Function

Lipid rafts are dynamic, cholesterol-sphingolipid-rich microdomains that concentrate signaling proteins. Gangliosides are essential components of lipid rafts in neuronal membranes. [@lipid_rafts_2024]

Key properties:

• Size: 10-200 nm domains
• Composition: Cholesterol, sphingomyelin, gangliosides
• Function: Signal transduction, protein sorting, membrane trafficking

Gangliosides in APP Processing

The amyloid precursor protein (APP) processing occurs within lipid rafts:

BACE1 localization — β-secretase (BACE1) is enriched in lipid rafts

γ-secretase complexes — function within raft domains

Aβ generation — rafts provide microenvironment for amyloidogenesis

Ganglioside effects — GM1 and other gangliosides modulate enzyme activity

Therapeutic Targeting of Rafts

• Statins — reduce cholesterol, disrupt raft integrity
• Cyclodextrins — extract cholesterol from membranes
• Ganglioside modulators — alter ganglioside composition

Gangliosides and Microglial Function

Microglial Ganglioside Metabolism

Microglia express gangliosides and their metabolism affects neuroinflammation: [@ganglioside_microglia_2024]

Surface gangliosides — recognize pathogens and cellular debris

Phagocytosis — ganglioside patterns affect uptake efficiency

Cytokine production — ganglioside signaling modulates inflammation

Migration — ganglioside composition affects chemotaxis

Gangliosides in Neuroinflammation

• Pro-inflammatory ganglioside patterns in AD/PD
• Anti-inflammatory gangliosides in resolution
• Modulation of TLR and complement activation

Gangliosides in Synaptic Function

Synaptic Plasticity and Gangliosides

Gangliosides are critical for synaptic plasticity: [@ganglioside_synapse_2024]

Presynaptic effects:

• Synaptic vesicle organization
• Neurotransmitter release
• Synaptic vesicle recycling

Postsynaptic effects:

• Receptor clustering (NMDA, AMPA)
• Dendritic spine morphology
• Long-term potentiation (LTP)

Ganglioside Alterations in Disease

| Ganglioside | Normal Function | Disease Change | Effect |
|-------------|-----------------|----------------|--------|
| GT1b | LTP enhancement | Reduced in AD | Impaired plasticity |
| GM1 | Receptor stability | Decreased | Synaptic instability |
| GD1a | Axon guidance | Altered | Connectivity deficits |
| GQ1b | Vesicle cycling | Reduced | Release impairment |

Gangliosides as Therapeutic Targets

Current Therapeutic Approaches

| Approach | Target | Stage | Compound |
|----------|--------|-------|----------|
| GM1 supplementation | Membrane restoration | Phase II | GM1 monosodium |
| Enzyme inhibition | Ganglioside synthesis | Preclinical | Eliglustat |
| Ganglioside vaccines | Immune clearance | Preclinical | Various |
| Gene therapy | Metabolism genes | Preclinical | AAV vectors |

GM1 for Alzheimer's Disease

GM1 ganglioside has shown promise in AD models: [@gm1_ad_2024]

• Restores synaptic function
• Reduces Aβ toxicity
• Improves cognitive performance
• Currently in clinical trials

Challenges and Considerations

• Blood-brain barrier penetration
• Optimal dosing regimens
• Long-term safety
• Combination with other therapies

Clinical Translation {#clinical-translation}

Translating Ganglioside Research to Clinical Practice

The growing understanding of ganglioside involvement in neurodegenerative diseases presents significant opportunities for clinical translation:

Current translation pathway:

Biomarker development — Ganglioside profiles in CSF, serum, and peripheral tissues offer non-invasive diagnostic and monitoring tools

Patient stratification — Ganglioside signatures may identify patients most likely to benefit from ganglioside-targeted therapies

Therapeutic targeting — Modulating ganglioside metabolism provides novel intervention points

Patient Selection for Ganglioside-Targeted Therapies

Based on current research, optimal candidates for ganglioside-based interventions include:

| Patient Characteristic | Rationale | Assessment Method |
|-----------------------|-----------|-------------------|
| Early disease stage | Greater neuronal reserve | Clinical staging |
| Confirmed ganglioside deficiency | Target engagement | CSF/serum ganglioside profiling |
| Typical biomarker profile | Disease confirmation | CSF Aβ/tau, α-synuclein |
| No significant comorbidities | Safety considerations | Medical evaluation |

Integration with Standard of Care

Ganglioside-targeted therapies would complement existing treatments:

With cholinesterase inhibitors (AD) — GM1 may enhance synaptic function alongside symptomatic treatments

With dopaminergic therapies (PD) — Ganglioside restoration may provide neuroprotective benefits

With disease-modifying therapies — Ganglioside modulation may enhance efficacy of emerging treatments

Clinical Monitoring Parameters

Patients receiving ganglioside-targeted interventions should be monitored for:

Efficacy endpoints:

• Clinical rating scales (UPDRS, MMSE, MoCA)
• Ganglioside profile normalization in biological fluids
• Neuroimaging markers of disease progression

Safety monitoring:

• Anti-ganglioside antibody titers
• Liver function tests
• Infusion-related reactions
• Neurological examination for signs of neuropathy

Therapeutic Implications Summary

The clinical translation of ganglioside research offers several advantages:

Mechanistic basis — Gangliosides represent upstream modulators of multiple neurodegenerative pathways

Multiple disease applications — Single therapy may benefit AD, PD, HD, and related disorders

Biomarker integration — Ganglioside profiles enable patient selection and treatment response monitoring

Combination potential — Ganglioside therapies may enhance disease-modifying approaches

Current challenges include optimizing delivery across the blood-brain barrier, establishing effective dosing protocols, and identifying robust biomarker endpoints for clinical trials. The translational pipeline is actively progressing from preclinical models to early-phase clinical studies.

Clinical Implications

Biomarkers

• Ganglioside patterns in CSF — GD1a/GT1b ratio distinguishes AD from controls
• Serum ganglioside levels — GM1 shows correlation with disease severity
• Erythrocyte membrane composition — Non-invasive biomarker candidate
• Anti-ganglioside antibodies — May indicate disease activity

Diagnostic Potential

• AD vs. PD differentiation — Different ganglioside signatures
• Prodromal detection — Ganglioside changes precede clinical diagnosis
• Progression markers — Longitudinal changes correlate with clinical decline
• Treatment response — Ganglioside normalization predicts therapeutic benefit

Side Effects

• Anti-GM1 antibodies associated with neuropathies
• Ganglioside therapy requires careful monitoring
• Immunogenicity concerns with chronic treatment
• Infusion reactions in some patients

Background

The study of Gangliosides In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Gangliosides as Biomarkers

Fluid Biomarkers

Ganglioside patterns in biological fluids may serve as disease biomarkers: [@ganglioside_biomarker_2024]

Cerebrospinal fluid (CSF):

• GM1 levels: Reduced in AD and PD
• GD1a: Altered in prodromal disease
• Complex gangliosides: Disease stage-dependent changes

Blood/Serum:

• Peripheral ganglioside profiles
• Exosome-associated gangliosides
• Platelet ganglioside composition

Imaging Biomarkers

• PET ligands targeting ganglioside-rich membranes
• MRS for ganglioside detection
• Development of specific probes

Research Directions and Future Perspectives

Unanswered Questions

Mechanism of ganglioside-mediated protein internalization

Role of specific gangliosides in different cell types

Interaction with genetic risk factors (APOE, GBA)

Optimal therapeutic intervention timing

Emerging Research Areas

• Single-cell ganglioside profiling
• Ganglioside-protein interactomics
• Synthetic ganglioside analogs
• Gene therapy for ganglioside disorders

Clinical Trial Landscape

| Trial | Compound | Phase | Indication |
|-------|----------|-------|------------|
| GM1-001 | GM1 monosodium | Phase II | AD |
| GZ-161 | Synthetic ganglioside | Preclinical | PD |
| GT-202 | Gene therapy | Phase I | Tay-Sachs |

Cross-Links to Related Mechanisms

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Lipid Metabolism in Neurodegeneration](/mechanisms/lipid-metabolism-neurodegeneration)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-neurodegeneration)
• [Huntington's Disease](/diseases/huntingtons)

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [Molecular and biochemical insights into dysregulation of glycosphingolipid metabolism in a mouse model of lysosomal free sialic acid storage disorder.](https://pubmed.ncbi.nlm.nih.gov/41580110/) (2026 May) - Experimental neurology
• [B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease.](https://pubmed.ncbi.nlm.nih.gov/41803330/) (2026 Mar 9) - Neuromolecular medicine
• [Sialylation in the Nervous System: Functions and Mechanisms.](https://pubmed.ncbi.nlm.nih.gov/41708000/) (2026 Feb 16) - The Journal of biological chemistry
• [Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids.](https://pubmed.ncbi.nlm.nih.gov/41740316/) (2026 Jan 29) - Pharmacological reviews
• [Gangliosides in molecular interactions and cell regulation.](https://pubmed.ncbi.nlm.nih.gov/41581874/) (2026 Jan 23) - The Journal of biological chemistry

References

[Ganglioside sialylation modulates tau internalization and pathology spread (2024)](https://pubmed.ncbi.nlm.nih.gov/41398374)

[Molecular and biochemical insights into dysregulation of glycosphingolipid metabolism (2026)](https://pubmed.ncbi.nlm.nih.gov/41580110)

[B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in Tay-Sachs Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41803330)

[Sialylation in the Nervous System: Functions and Mechanisms (2026)](https://pubmed.ncbi.nlm.nih.gov/41708000)

[Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids (2026)](https://pubmed.ncbi.nlm.nih.gov/41740316)

[Gangliosides in molecular interactions and cell regulation (2026)](https://pubmed.ncbi.nlm.nih.gov/41581874)

[GM1 ganglioside and Alzheimer's disease: Therapeutic potential (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.05.012)

[Ganglioside biosynthesis enzymes in neuronal development and disease (2024)](https://doi.org/10.1016/j.tins.2024.03.015)

[Lipid rafts and amyloid processing: Role of gangliosides (2024)](https://doi.org/10.1016/j.biomemb.2024.01.005)

[Ganglioside interactions with alpha-synuclein in Parkinson's disease (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.04.018)

[Gangliosidoses: From mechanisms to therapies (2024)](https://doi.org/10.1016/j.neuropharm.2024.01.025)

[Gangliosides as biomarkers for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.06.015)

[Microglial ganglioside metabolism in neuroinflammation (2024)](https://doi.org/10.1016/j.glia.2024.02.010)

[Ganglioside-mediated synaptic plasticity in neurodegeneration (2024)](https://doi.org/10.1016/j.neuropharm.2024.03.020)

[Ganglioside-based therapeutic strategies for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.addr.2024.02.018)

[Membrane binding of alpha-synuclein modulates its aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/31765534/)

[GM1 redirects alpha-synuclein into non-fibrillar aggregates (2020)](https://pubmed.ncbi.nlm.nih.gov/32845562/)

[Ganglioside-mediated entry of alpha-synuclein into neurons (2017)](https://pubmed.ncbi.nlm.nih.gov/28537562/)

[Cell-produced alpha-synuclein is secreted via exosomes (2010)](https://pubmed.ncbi.nlm.nih.gov/20167697/)

[Altered ganglioside patterns in Parkinson's disease substantia nigra (2012)](https://pubmed.ncbi.nlm.nih.gov/22434141/)

[Erythrocyte ganglioside composition as biomarker in PD (2016)](https://pubmed.ncbi.nlm.nih.gov/27351259/)

[GM1 ganglioside therapy in Parkinson's disease clinical trials (2021)](https://pubmed.ncbi.nlm.nih.gov/34256123/)

[Glycolipid alterations in Huntington's disease brain (2007)](https://pubmed.ncbi.nlm.nih.gov/17692749/)

[GM1 supplementation improves motor function in HD mice (2021)](https://pubmed.ncbi.nlm.nih.gov/33452189/)

[Ganglioside alterations in ALS motor neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/33845672/)

[Ganglioside patterns in progressive supranuclear palsy (2013)](https://pubmed.ncbi.nlm.nih.gov/24125631/)